A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
Recruiting · NCT07751991 · Registry updated 2026-10-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-10-08 | NCT07751991 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Charm Therapeutics | 1 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope Center Medical Center | Duarte | United States | 1 |
| Oxford University Hospitals NHS Foundation Trust | Oxford | United Kingdom | 15 |
| START Midwest | Grand Rapids | United States | 79 |
| Yale - New Haven Hospital / Cancer Center | New Haven | United States | 1 |